Avaii Wealth Management LLC decreased its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 54.5% in the first quarter, HoldingsChannel.com reports. The fund owned 4,207 shares of the biopharmaceutical company’s stock after selling 5,037 during the quarter. Avaii Wealth Management LLC’s holdings in Pfizer were worth $218,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank OZK boosted its position in Pfizer by 0.3% during the 4th quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock valued at $4,067,000 after acquiring an additional 195 shares in the last quarter. TimeScale Financial Inc. lifted its holdings in shares of Pfizer by 2.9% during the 4th quarter. TimeScale Financial Inc. Now owns 6,978 shares of the biopharmaceutical company’s stock valued at $412,000 after purchasing an additional 196 shares during the last quarter. Fruth Investment Management lifted its holdings in shares of Pfizer by 0.7% during the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $1,730,000 after purchasing an additional 200 shares during the last quarter. Winfield Associates Inc. lifted its holdings in shares of Pfizer by 0.9% during the 4th quarter. Winfield Associates Inc. Now owns 21,557 shares of the biopharmaceutical company’s stock valued at $1,273,000 after purchasing an additional 200 shares during the last quarter. Finally, Birinyi Associates Inc. its raised stake in Pfizer by 3.4% in the 1st quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 200 during the last quarter. 66.50% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently issued reports on the company. The Goldman Sachs Group set a $51.00 target price on Pfizer in a research note on Wednesday, May 25th. Morgan Stanley initiated coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price objective for the company. Barclays set a $52.00 price objective on Pfizer in a research note on Tuesday, May 17th. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, May 3rd. Finally, Citigroup lifted their objective price on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $57.26.
PFE stock opened at $51.59 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. The business has a 50 day simple moving average of $50.48 and a 200-day simple moving average of $52.21. The firm has a market capitalization of $289.47 billion, a PE ratio of 11.83, a price-to-earnings-growth ratio of 0.61 and a beta of 0.76. Pfizer Inc. has a 1 year low of $38.82 and a 1 year high of $61.71.
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. During the same quarter in the prior year, the company posted $0.93 earnings per share. The company’s revenue was up 76.8% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 6.61 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annual basis and a yield of 3.10%. The ex-dividend date is Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is 36.70%.
In other news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares in the company, valued at $585,250.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the sale, the senior vice president now owns 15,064 shares in the company, valued at $760,732. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock worth $2,075,003 over the last 90 days. 0.05% of the stock is owned by insiders.
Pfizer Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.